Home › Diffuse Large B-Cell Lymphoma › Massachusetts › Boston
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Boston, MA
16 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Boston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 3
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Nagre-recruitPhase 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Nagre-recruitPhase 2
- Boston Medical Center, Boston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Nagre-recruitObservasyonal na pag-aaral
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Nagre-recruitPhase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pag-aaral para sa Diffuse Large B-Cell Lymphoma sa ibang lungsod
- New York City, NY21 pag-aaral
- Baldwin Park, CA19 pag-aaral
- Chicago, IL18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Houston, TX17 pag-aaral
- Milwaukee, WI16 pag-aaral
- Portland, OR15 pag-aaral
- Philadelphia, PA15 pag-aaral
- Nashville, TN14 pag-aaral
- Durham, NC14 pag-aaral
- Dallas, TX13 pag-aaral
- Washington, DC12 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso110 pag-aaral
- Non-Small Cell Lung Cancer89 pag-aaral
- Kanser (lahat ng uri)86 pag-aaral
- Colorectal Cancer63 pag-aaral
- Metastatic Cancer63 pag-aaral
- Kanser sa Ovary62 pag-aaral
- Kanser sa Baga62 pag-aaral
- Kanser sa Prostate61 pag-aaral
- Depression51 pag-aaral
- Kanser ng Endometrium50 pag-aaral
- Acute Myeloid Leukemia45 pag-aaral
- Kanser sa Pancreas44 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Set 29, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.